In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Albireo Pharma (ALBO – Research Report), with a price target of $75.00. The company's shares closed last Wednesday at $36.85, close to its 52-week high of $37.86. According to TipRanks.com, Argyrides is a 1-star analyst with an average return of -12.5% and a 36.4% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Clearside Biomedical, and Kala Pharmaceuticals. Currently, the analyst consensus on Albireo Pharma is a Strong Buy with an average price target of $74.75, which is an 113.0% upside from current levels.
https://www.tipranks.com/news/blurbs/wedbush-believes-albireo-pharma-albo-still-has-room-to-grow?utm_source=advfn.com&utm_medium=referral